The Role of Turnover and Inflammation in Bone

Links

URL: https://hdl.handle.net/2027.42/177887

Abstract

Bone is in a constant state of remodeling in response to metabolic needs and to maintain structure. While osteoblasts and osteoclasts are under tight temporal and spatial regulation to maintain bone mass, macrophages traditionally associated with immune responsibilities also contribute to homeostasis. Bone formation is supported by osteal macrophage efferocytosis (phagocytosis of apoptotic cells). There are numerous clinical conditions associated with both defective macrophage function and bone, including osteoporosis, in which bone resorption outpaces bone formation. It is estimated that more than 10 million patients are living with osteoporosis in the US, resulting in decreased bone mineral density and increased stress fracture risk. Although parathyroid hormone (PTH) has been FDA approved since 2002 as an anabolic agent for the treatment of osteoporosis and has been investigated for decades, its mechanism is still not fully defined. This thesis sought to contribute to the understanding of macrophage function in bone biology, in conjunction with anabolic PTH and stress fracture healing. We evaluated more than 90 murine models relative to bone formative actions with a primary focus on the trabecular compartment, revealing trends in critical genes and gene families relevant to PTH anabolic actions. Gene deletions with the greatest increase in trabecular bone volume in response to PTH include PTH and 1-α-hydroxylase, amphiregulin, and PTH-related protein. Effects of PTH treatment in macrophage depletion models was dependent on the target. While early lineage depletion models (macrophage Fas-induced apoptosis mouse) had a decreased anabolic response, late lineage depletion models (clodronate liposome induced apoptosis) had an enhanced anabolic response attributed to macrophage recruitment, indicating osteal macrophages play an integral role in the osteoinductive effect of PTH. Next, we evaluated stress fracture healing with PTH treatment. By one week of healing, PTH enhanced callus bone volume. Earlier histological evaluation showed significantly more macrophages in the callus with PTH. Treatment with FDA-approved chemotherapeutic trabectedin showed a decrease in callus macrophages and smaller callus bone volume. The callus macrophages and bone volume were synergistic, supporting a role for macrophages in enhanced stress fracture healing. To have a better understanding of macrophages in bone, we considered one of their main functions, efferocytosis. When macrophages efferocytosed apoptotic bone marrow stromal cells (apBMSCs), 1219 genes significantly up- or down-regulated genes compared to macrophages alone, with SerpinB2 being the most upregulated (9.69x higher during efferocytosis). SerpinB2 is a serine protease inhibitor, but its biological role in bone has not been fully elucidated. We hypothesized that stress fracture healing, under global inflammatory conditions with LPS treatment, would be delayed in SerpinB2 KO mice. With loss of SerpinB2, there was a greater reduction in stress fracture healing with LPS treatment. WT and KO macrophages in vitro had similar phagocytic function. Macrophages exist on a continuum from M1-like (pro-inflammatory) to M2-like (pro-resolving). LPS-treated KO macrophages had lower expression of M1 marker Cd86 but no change in M2 marker Cd206, suggesting that M1-like macrophages are more impacted by the loss of SerpinB2. This is supported by our data showing no differences in outcomes where the M2-like macrophage dominates: one week of stress fracture healing and phagocytosis, suggesting a differential role of SerpinB2 in M1-like and M2-like macrophages. Overall, this dissertation contributes to the understanding of bone biology with clinical motivation, including the anabolic actions of PTH, macrophages in stress fracture healing, and SerpinB2 in bone and macrophage physiology.

Cited Works (17)

Year	Entry
2012	Claes L, Recknagel S, Ignatius A. Fracture healing under healthy and inflammatory conditions. Nat Rev Rheumatol. March 2012;8(3):133-143.
2000	Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. April 2000;21(2):115-137.
2010	Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. July 2010;25(7):1468-1486.
2009	Colnot C. Skeletal cell fate decisions within periosteum and bone marrow during bone regeneration. J Bone Miner Res. February 2009;24(2):274-282.
1997	Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. August 23, 1997;350(9077):P550-P555.
2005	Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. November 2005;146(11):4577-4583.
1998	Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res. May 1998;13(5):793-802.
1997	Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res. January 1997;12(1):6-15.
1981	Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption: a hypothesis. Calcif Tiss Int. December 1981;33(1):349-351.
2020	Yorgan TA, Rolvien T, Stürznickel J, Vollersen N, Lange F, Zhao W, Baranowsky A, Rosenthal L, Hermans‐Borgmeyer I, Sharaf A, Karsak M, David J, Oheim R, Amling M, Schinke T. Mice carrying a ubiquitous R235W mutation of Wnt1 display a bone‐specific phenotype. J Bone Miner Res. September 2020;35(9):1726-1737.
2020	Yorgan TA, Sari H, Rolvien T, Windhorst S, Failla AV, Kornak U, Oheim R, Amling M, Schinke T. Mice lacking plastin-3 display a specific defect of cortical bone acquisition. Bone. January 2020;130:115062.
1997	Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao Y-H, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. May 30, 1997;89(5):755-764.
2007	LeBlanc AD, Spector ER, Evans HJ, Sibonga JD. Skeletal responses to space flight and the bed rest analog: a review. J Musculoskel Neuron Interact. 2007;7(1):33-47.
1999	Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. August 1999;104(4):439-446.
2001	Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. NEJM. May 10, 2001;344(19):1434-1441.
2016	Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. NEJM. October 20, 2016;375(16):1532-1543.
2021	Hrdlicka HC, Pereira RC, Shin B, Yee S-P, Deymier AC, Lee S-K, Delany AM. Inhibition of miR-29-3p isoforms via tough decoy suppresses osteoblast function in homeostasis but promotes intermittent parathyroid hormone-induced bone anabolism. Bone. February 2021;143:115779.